Our mission
From healthcare data to decision-ready evidence,helping treatments reach patients earlier.
Our mission is to make clinical development a continuous learning process—so each study builds on existing knowledge and brings effective treatments closer to patients.
Evinexus builds digital twin cohorts from real-world oncology data, so sponsors can plan trials that need fewer patients and reach decisions earlier.
Most trials relearn what earlier studies already showed.
Each randomized trial enrolls its own control arm, even when earlier trials and routine care have already shown how patients on the standard of care fare. That adds enrollment and follow-up time, asks more patients to take the comparator, and keeps rigorous trials out of reach for many smaller sponsors and rarer cancers.
We believe what one study learns should strengthen the next.
What changes when each study builds on existing knowledge.
Smaller control arms.
Digital twin cohorts can supplement or stand in for a trial's control arm, so more enrolled patients receive the treatment under study.
Earlier decisions.
Existing control evidence can bring a trial's primary analysis forward, and feasibility and design questions can be tested before the first patient enrolls.
Trials within reach of more sponsors.
Smaller trials let smaller sponsors pursue rigorous development, including in cancers too rare to fill a large control arm.
Evidence that holds up to review.
Each cohort is reviewed by clinicians and tested by reproducing completed randomized trials, without exposing any individual's records.
Room to test more promising treatments.
When each trial builds on what is already known, the same patients and time can test more treatments, including in patient populations that conventional trial designs leave behind.
Discuss your next study